Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07816367 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date pushed from Sep 2026 to Oct 2026 Show 1 more changeShow less
    • Start date pushed from Sep 2026 to Oct 2026
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Sep 2027 to Oct 2027 · Start date: Sep 2026 to Oct 2026 · Site details revised at 72 of 72 sites Show 3 more changesShow less
    • Primary completion date: Sep 2027 to Oct 2027
    • Start date: Sep 2026 to Oct 2026
    • Site details revised at 72 of 72 sites
  3. Re-verified, no change to tracked fields
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kallyope Inc.
4 trials monitored
See all monitored trials
Migraine
467 trials monitored
See 24 trials at risk
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
Trial Details
NCT Number NCT07816367
Lead Sponsor Kallyope Inc.
Conditions Migraine
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov